<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment with AS-AT did not inhibit ACE activity whereas standard ACE inhibitor, captopril, inhibited the ACE activity around 53% (
 <xref ref-type="fig" rid="fig8">Figure 8(a)</xref>). Treatment with AS-AT did not alter the erythrocyte carbonic anhydrase activity whereas typical carbonic anhydrase inhibitor, acetazolamide, inhibited it by 55 ± 5% (
 <xref ref-type="fig" rid="fig8">Figure 8(b)</xref>). Moreover, AS-AT (3–30 
 <italic>μ</italic>M) did not change 
 <italic>in vitro</italic> renal Na+/K+/ATPase activity (
 <xref ref-type="fig" rid="fig8">Figure 8(c)</xref>).
</p>
